Piper Sandler on Tyra Biosciences (TYRA): 'We're incrementally positive on dabogratinib's commercial opportunity'
Tweet Send to a Friend
Piper Sandler analyst Allison Bratzel reiterated an Overweight rating and $56.00 price target on Tyra Biosciences (NASDAQ: TYRA).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
